Picture of Zhaoke Ophthalmology logo

6622 — Zhaoke Ophthalmology News Story

0.000.00%
hk flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

Brief: Zhaoke Ophthalmology Says Clinical Trial Met Primary Efficacy Endpoint

Oct 13 (Reuters) - Zhaoke Ophthalmology Ltd  6622.HK :
    * ONE-YEAR PHASE III CLINICAL TRIAL OF NVK002 SUCCESSFULLY
MET ITS
PRIMARY EFFICACY ENDPOINT

Source text for Eikon:  ID: 
Further company coverage:  6622.HK 

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Zhaoke Ophthalmology

See all news